JDRF Blog

Ashlynn O’Hara is 10 years old, lives with type 1 diabetes (T1D), and is taking her fight for affordable continuous glucose monitors (CGM) to the big leagues.

The results of the Ontario budget mean that your voice is now more important than ever. You can immediately support this initiative by writing, calling or meeting with your provincial or territorial representative by simply clicking here.

Having someone with the lived experience of diabetes relate their struggles with maintaining good blood glucose to political representatives and get across just how life-changing, in some cases life-saving, CGM and FGM devices can be, changes the whole conversation.

This month, twenty years ago, a pioneering clinical trial in Alberta marked a major advancement in islet transplantation for the treatment of type 1 diabetes (T1D).

We are pleased to announce Dr. Sarah Linklater has been appointed as Chief Scientific Officer (CSO).

Recently, a team of researchers in the United States developed a test to identify individuals of African descent who are more likely to get the disease.

Dr. Esteban N. Gurzov, a talented young scientist from Brussels, Belgium, was recently named the first recipient of JDRF’s Dr. Robert Goldstein Award.

From Walk participant to trial participant to T1D advocate, here is Ash Hunkin’s story.

Dr. Rémi Rabasa-Lhoret, a JDRF-funded endocrinologist at the Institut de recherches cliniques de Montréal best known for his work on the artificial pancreas, is overseeing the initiative to collect data for the Quebec-wide registry of people with T1D in order to track the incidence of hypoglycemic episodes and allow patients to better manage their disease.

Does Vitamin D play a role in developing type 1 diabetes (T1D)?

Administering insulin on a daily basis can be a tedious task, particularly among individuals newly diagnosed with type 1 diabetes (T1D). To mitigate this, researchers are currently experimenting with islet (insulin-producing cells) transplantation as a promising therapy that eliminates the need for insulin injections.

Since 2016, JDRF and Sernova Corp., a clinical-stage regenerative medicine company, have been collaborating on innovative technology to treat hypoglycaemia (low sugar) unawareness in patients with severe T1D.